Evaluation of therapeutic response and tolerability to intravenous iron sucrose and ferric carboxymaltose among pregnant women with iron?deficiency anemia: A 6?year experience in a tertiary care center
- PMID: 40242215
- PMCID: PMC12001210
- DOI: 10.3892/mi.2025.233
Evaluation of therapeutic response and tolerability to intravenous iron sucrose and ferric carboxymaltose among pregnant women with iron?deficiency anemia: A 6?year experience in a tertiary care center
Abstract
Iron-deficiency anemia (IDA) is a global health concern in pregnancy associated with adverse fetal and maternal outcomes. The present study aimed to evaluate and compare the therapeutic response and tolerability of intravenous (IV) iron sucrose and ferric carboxymaltose (FCM) administered to pregnant women with IDA. The present prospective observational study was conducted among 334 pregnant women who were in the second or third trimester of pregnancy with moderate to severe IDA and who were treated with IV iron sucrose or FCM at a large tertiary care center between April, 2018 and March, 2024. The therapeutic response was assessed by analyzing the increase in hemoglobin (Hb) and serum ferritin levels at 3 and 6 weeks following the first dose of IV iron treatment. Tolerability was assessed by analyzing the adverse events to drug administration. A statistically significant increase in the mean Hb and serum ferritin levels was observed in both the iron sucrose and FCM groups at 3 and 6 weeks post-infusion (P<0.0001 for all); however, the increase in the FCM group was significantly higher (P<0.0001) than that in the iron sucrose group. Minor temporary adverse drug reactions were comparable (P=0.232) between the both treatment groups, with no major serious adverse events observed in any group. IV iron sucrose and FCM both were efficacious and well tolerated in pregnant women with moderate to severe IDA during the second and third trimester. However, there was an improved overall response to FCM as it caused a greater increase in the Hb and serum ferritin levels than iron sucrose. Therefore, FCM is recommended as an effective and safe alternative to iron sucrose for the treatment of IDA during pregnancy.
Keywords: ferric carboxymaltose; intravenous iron; iron sucrose; iron-deficiency anemia; pregnancy.
Copyright: © 2025 Patel et al.
Conflict of interest statement
All authors declare that they have no competing interests.
Similar articles
-
A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.Semin Hematol. 2018 Oct;55(4):223-234. doi: 10.1053/j.seminhematol.2018.04.006. Epub 2018 Apr 25. Semin Hematol. 2018. PMID: 30502851 Clinical Trial.
-
Ferric carboxymaltose: A revolution in the treatment of postpartum anemia in Indian women.Int J Appl Basic Med Res. 2015 Jan-Apr;5(1):25-30. doi: 10.4103/2229-516X.149230. Int J Appl Basic Med Res. 2015. PMID: 25664264 Free PMC article.
-
REGAIN STUDY: Retrospective Study to Assess the Effectiveness, Tolerability, and Safety of Ferric Carboxymaltose in the Management of Iron Deficiency Anemia in Pregnant Women.Anemia. 2019 Nov 12;2019:4640635. doi: 10.1155/2019/4640635. eCollection 2019. Anemia. 2019. PMID: 31781389 Free PMC article.
-
Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: A systematic review and meta-analysis.Medicine (Baltimore). 2021 May 21;100(20):e24571. doi: 10.1097/MD.0000000000024571. Medicine (Baltimore). 2021. PMID: 34011020 Free PMC article.
-
A meta-analysis of ferric carboxymaltose versus other intravenous iron preparations for the management of iron deficiency anemia during pregnancy.Rev Bras Ginecol Obstet. 2024 Mar 15;46:e-rbgo21. doi: 10.61622/rbgo/2024AO21. eCollection 2024. Rev Bras Ginecol Obstet. 2024. PMID: 38765534 Free PMC article. Review.
References
-
- Bencaiova G, Burkhardt T, Breymann C. Anemia-prevalence and risk factors in pregnancy. Eur J Intern Med. 2012;23:529–533. - PubMed
-
- Ministry of Health and Family Welfare, Government of India: National Family Health Survey (NFHS-5) 2019-2021, Compendium of fact sheets. Ministry of Health and Family Welfare, Government of India, New Delhi, 2020. https://main.mohfw.gov.in/sites/default/files/NFHS-5_Phase-II_0.pdf. Accessed January 30, 2024.
LinkOut - more resources
Full Text Sources
Miscellaneous